Recent and conclusive genetic evidence has demonstrated that SGLT2i can act independently of SGLT2 to ameliorate HF in mice, since SGLT2i produce beneficial cardiac effects in HFrEF and ischemia models even in germline SGLT2-knockout mice (20, 21, 24). This evidence concerns the gene SLC5A2 and ischemia.